Revised international prognostic scoring system for myelodysplastic syndromes.
暂无分享,去创建一个
Luca Malcovati | Pierre Fenaux | Mario Cazzola | John M Bennett | Guillermo Garcia-Manero | Peter Valent | Francesc Solé | Christa Fonatsch | M. Cazzola | F. Solé | M. L. Le Beau | A. Levis | P. Greenberg | M. Slovak | H. Kantarjian | G. Garcia-Manero | J. Maciejewski | J. Bennett | P. Fenaux | C. Fonatsch | P. Valent | M. Sekeres | M. Pfeilstöcker | W. Sperr | U. Germing | Y. Miyazaki | L. Malcovati | D. Bowen | J. Čermák | A. A. van de Loosdrecht | R. Stauder | S. Tauro | G. Sanz | F. Dreyfus | Hagop Kantarjian | Peter L Greenberg | Heinz Tuechler | Julie Schanz | Guillermo Sanz | David Bowen | Francois Dreyfus | Andrea Kuendgen | Alessandro Levis | Jaroslav Cermak | Michelle M Le Beau | Marilyn L Slovak | Otto Krieger | Michael Luebbert | Jaroslaw Maciejewski | Silvia M M Magalhaes | Yasushi Miyazaki | Michael Pfeilstöcker | Mikkael Sekeres | Wolfgang R Sperr | Reinhard Stauder | Sudhir Tauro | Teresa Vallespi | Arjan A van de Loosdrecht | Ulrich Germing | Detlef Haase | T. Vallespí | O. Krieger | H. Tuechler | D. Haase | J. Schanz | S. Magalhães | A. Kuendgen | M. Luebbert
[1] C. Bloomfield,et al. NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. , 2011, Journal of the National Comprehensive Cancer Network : JNCCN.
[2] C. Bloomfield,et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.
[3] Jean McGowan-Jordan,et al. ISCN 2013 : an international system for human cytogenetic nomenclature (2013) : recommendations of the International Standing Committee on Human Cytogenetic Nomenclature , 2005 .
[4] V. V. D. van der Velden,et al. Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. , 2008, Blood.
[5] M. Cazzola,et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS) , 2011, Haematologica.
[6] C. Fonatsch,et al. Prognostic value of lactate dehydrogenase activity in myelodysplastic syndromes. , 2001, Leukemia research.
[7] C. Gross,et al. Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes. , 2009, Leukemia research.
[8] A. Verma,et al. Cytokine targets in the treatment of myelodysplastic syndromes. , 2005, Current hematology reports.
[9] Luca Malcovati,et al. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome , 2011, Haematologica.
[10] A. Órfão,et al. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group , 2012, Leukemia.
[11] C. Steidl,et al. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS) , 2005, Leukemia.
[12] C. Declercq,et al. Prognostic factors in myelodysplastic syndromes: critical analysis of the impact of age and gender and failure to identify a very‐low‐risk group using standard mortality ratio techniques , 1996, British journal of haematology.
[13] L. Arenillas,et al. Independent Impact of Iron Overload and Transfusion Dependency on Survival and Leukemic Evolution in Patients with Myelodysplastic Syndrome , 2008 .
[14] M. Sanz,et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. , 1989, Blood.
[15] C. Fonatsch,et al. Prognostic significance of serial determinations of lactate dehydrogenase (LDH) in the follow-up of patients with myelodysplastic syndromes. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] A. Hagemeijer,et al. Additional prognostic value of bone marrow histology in patients subclassified according to the International Prognostic Scoring System for myelodysplastic syndromes. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] P. Valent,et al. Impact of age and comorbidity in myelodysplastic syndromes. , 2008, Journal of the National Comprehensive Cancer Network : JNCCN.
[18] C. Bloomfield,et al. The 2008 Revision of the WHO Classification of Myeloid Neoplasms and Acute Leukemia : Rationale and Important Changes , 2009 .
[19] D. Costa,et al. The degree of neutropenia has a prognostic impact in low risk myelodysplastic syndrome. , 2012, Leukemia research.
[20] M. Cazzola,et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] M. Cazzola,et al. 14 Revised International Prognostic Scoring System (IPSS-R), developed by the International Prognostic Working Group for Prognosis in MDS (IWG-PM) , 2011 .
[22] A. Ganser,et al. Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes , 2008, Leukemia.
[23] D. Neuberg,et al. Clinical effect of point mutations in myelodysplastic syndromes. , 2011, The New England journal of medicine.
[24] C E Minder,et al. A robust method for proportional hazards regression. , 1996, Statistics in medicine.
[25] P. Valent,et al. Comorbidity as Prognostic Variable in MDS: Comparative Evaluation of the HCT-CI and CCI in a Core Data Set of 582 Patients of the Austrian MDS Platform. , 2008 .
[26] P. Greenberg,et al. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: Impact of cytopenias on clinical outcomes in myelodysplastic syndromes , 2008, American journal of hematology.
[27] H. Kantarjian,et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes , 2007, Cancer.
[28] P. Valent,et al. Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[29] T Hamblin,et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.
[30] J. Issa,et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System , 2008, Cancer.
[31] M. Suarez‐Almazor,et al. Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] References , 1971 .
[33] C. Steidl,et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] Ken Chen,et al. Clonal architecture of secondary acute myeloid leukemia. , 2012, The New England journal of medicine.
[35] U. Germing,et al. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. , 1992, Leukemia.
[36] M. Pfeilstöcker,et al. Time changes in predictive power of established and recently proposed clinical, cytogenetical and comorbidity scores for Myelodysplastic Syndromes. , 2012, Leukemia research.
[37] Y. Rumpler,et al. International Standing Committee on Human Cytogenetic Nomenclature , 1976 .
[38] F. Harrell,et al. Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .
[39] M. Ardanaz,et al. Prognostic impact of severe thrombocytopenia in low‐risk myelodysplastic syndrome , 2011, Cancer.
[40] Luca Malcovati,et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] T M Therneau,et al. Diagnostic plots to reveal functional form for covariates in multiplicative intensity models. , 1995, Biometrics.
[42] H. Deeg,et al. Negative Regulators of Hemopoiesis and Stroma Function in Patients with Myelodysplastic Syndrome , 2000, Leukemia & lymphoma.
[43] U. Germing,et al. Levels of beta 2 microglobulin have a prognostic relevance for patients with myelodysplastic syndrome with regard to survival and the risk of transformation into acute myelogenous leukemia. , 2009, Leukemia research.
[44] A. Stamatoullas,et al. Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDS. , 2011, Leukemia research.
[45] E. Estey,et al. Contribution of beta-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS). , 2003, Blood.
[46] H. Gralnick,et al. Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.
[47] Sonali M. Smith,et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. , 2003, Blood.
[48] U. Germing,et al. The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome , 2009, Haematologica.
[49] M. Cazzola,et al. Syndromes Revised International Prognostic Scoring System for Myelodysplastic , 2012 .
[50] C. Bloomfield,et al. Myelodysplastic SyndromesPractice Guidelines in Oncology , 2011 .
[51] U. Germing,et al. Myelodysplastic syndromes in patients younger than age 50. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] M. Stratton,et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. , 2011, The New England journal of medicine.
[53] M. Lübbert,et al. Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[54] M. Cazzola,et al. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.